Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk A/S ($NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...